10x Genomics Inc Class A (TXG)

The past six months have seen several events impacting 10X Genomics' stock price. In Q2 2025, the company reported an EPS of $0.277. In Q3 2025, 10X Genomics announced an EPS of -$0.22, exceeding the consensus estimate, with revenue of $149.00 million, also exceeding estimates. Analyst ratings and price targets were adjusted by several firms, including Zacks Research, Piper Sandler, Wall Street Zen, Morgan Stanley, TD Cowen and Leerink Partners. 10X Genomics stock reached a 52-week high of $21.52 USD on January 20, 2026. As of February 6, 2026, the closing price was $18.61, and the market capitalization as of January 26, 2026, was $2.863 billion, showing a 57.64% improvement over the past 12 months.

Historically, the demand for 10X Genomics' products and services tends to exhibit some seasonality. Implied volatility for TXG has historically risen most significantly in February, with a median IV of 72.9. Conversely, September has typically seen implied volatility decline to its lowest levels, with a median IV of 47.0. This suggests that demand or market activity related to TXG's stock and potentially its underlying business may experience fluctuations throughout the year, with a potential peak in the early part of the year and a trough in the fall.

10X Genomics, Inc. is a life science technology company that develops and sells instruments, consumables, and software for analyzing biological systems. The company operates within the Healthcare sector, specifically in the Health Information Services and Healthcare Equipment & Supplies industries. Its integrated solutions enable researchers to understand biological analytes within tissues at high resolution and analyze individual biological components. Major products include the Chromium platform for analyzing individual biological components, the Visium platform for understanding the spatial positions of biological analytes within tissues, and the Xenium platform for in situ analysis. 10X Genomics serves a diverse client base, including academic, government, biopharmaceutical, biotechnology, and other institutions.

10X Genomics has a global presence, selling its products and solutions across various regions including the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.

In the past year, 10X Genomics has maintained a positive brand reputation through strategic collaborations and its role in advancing scientific research. The company partnered with PharosAI for AI-driven cancer research and with Dana-Farber Cancer Institute to analyze tumor samples and research cancer treatment responses. 10x Genomics also announced a collaboration with Brigham & Women's Hospital to study blood samples from patients with autoimmune diseases. These collaborations highlight the company's commitment to scientific advancement and its technologies' critical role in various fields.

10X Genomics, Inc. has a broad ownership base, with significant institutional holdings. 515 institutional owners and shareholders hold a total of 147,223,375 shares. Major institutional owners include Vanguard Group Inc., ARK Investment Management LLC, BlackRock, Inc., Fmr Llc, Sumitomo Mitsui Trust Holdings, Inc., Millennium Management Llc, Wellington Management Group Llp, and Quantinno Capital Management LP. Founders Serge Saxonov, Ben Hindson, and Kevin Ness launched the company in 2012-2013 and held meaningful stakes, which were diluted through subsequent private financings as the company grew towards its IPO in September 2019.